One Little Pill

Last updated

One Little Pill [1]
One Little Pill Official Movie Poster.jpg
Directed byAdam Schomer [1]
Written byAdam Schomer
Produced byAdam Schomer
Claudia Christian
Narrated by Claudia Christian [1]
CinematographyScott Mathias Chrisman
Edited byBarry Rubinow
Music byMichael Mollura
Production
companies
Zard Productions
i2i Productions
Release dates
  • August 23, 2014 (2014-08-23)(HollyShorts Film Festival)
  • October 1, 2014 (2014-10-01)
Running time
50 minutes
CountryUnited States
LanguageEnglish

One Little Pill is a documentary film about the use of generic medications (primarily naltrexone, but also nalmefene) for treating and curing alcoholism. The primary focus is on the Sinclair method, which pairs these medications with continued drinking. It was produced by Zard Productions as a film project for the C Three Foundation and released on Vimeo and VHX for on-demand viewing in October 2014. As of August 2015, DVD-R copies are also available. [1] [2] [3]

Contents

Synopsis

One Little Pill is a documentary film about the Sinclair method of treating alcohol abuse. [2] The film follows the lives of several people who have suffered from alcoholism, and have been helped by the treatment. Perspectives from scientists, treatment centers, doctors, and a legal prosecutor are also presented.

Claudia comes across as really down to earth and wanting to help others, and helps bring the different elements of the film together. This certainly makes a welcome change, to celebrities going on about the 12-step solution.

Michael D. (Lovinglife52), Recovering From Recovery [4]

The film describes the application of opioid blockers (naltrexone or nalmefene) as an alternative to help alcohol addicts in place of other more mainstream solutions such as twelve-step programs. The treatment is claimed by the C Three Foundation to have a 78% success rate in remedying alcohol dependence. [2] [5] :p. 293 Naltrexone is FDA approved for use in the United States. In 2013/4 the Scottish Medicines Consortium (SMC) approved nalmefene for use as part of the NHS National Services Scotland. [2] Some studies have shown the treatment to be effective in reducing the urge to drink. [6] [7]

The treatment is described in the film as follows: a single dosage of naltrexone is taken one hour before drinking alcohol, but not on other occasions. Over the following months, most users will begin to drink alcohol less frequently or in smaller quantities. Usually after 3 to 4 months (but occasionally 15 months), successful practitioners are no longer addicted; some people give up drinking alcohol altogether, while others become social drinkers. If they choose to continue to drink, the patients have to continue taking the drug as needed for life. Therapy may optionally also be used. [2] [5] [8]

Release

In July 2014 the first sale of the documentary was announced. YLE TV Finland showed the film in March 2015 and the film page received more than 14,000 views. [9] [10]
A special showing of the film occurred on August 23, 2014 at the HollyShorts Film Festival. [11] [12]
Purchase and rental of the move via Video on Demand was announced in September 2014. [2]

Production

The executive producers Adam Schomer and Claudia Christian financed the film by a campaign on the crowd funding website Indiegogo, [1] with additional finance from Fundly, general donations and special fund raisers. The film was made by the C Three Foundation, a nonprofit organization created by actress Claudia Christian. She is a proponent of the Sinclair method, which she credits for saving her life in 2009. [5] [13]

See also

Related Research Articles

<span class="mw-page-title-main">Alcoholics Anonymous</span> Sobriety-focused mutual help fellowship

Alcoholics Anonymous (AA) is a global peer-led mutual aid fellowship begun in the United States dedicated to abstinence-based recovery from alcoholism through its spiritually inclined twelve-step program. AA's twelve traditions, besides stressing anonymity, establish it as non-professional, unafiliated, non-denominational and apolitical with a public relations policy stressing attraction rather than promotion. In 2020 AA estimated a worldwide membership of over two million, with 75% of those in the US and Canada.

<span class="mw-page-title-main">Alcoholism</span> Problematic excessive alcohol consumption

Alcoholism is the continued drinking of alcohol despite negative results. Problematic use of alcohol has been mentioned in the earliest historical records, the World Health Organization (WHO) estimated there were 283 million people with alcohol use disorders worldwide as of 2016. The term alcoholism was first coined in 1852, but alcoholism and alcoholic are stigmatizing and discourage seeking treatment, so clinical diagnostic terms such as alcohol use disorder or alcohol dependence are used instead.

<span class="mw-page-title-main">Alcohol abuse</span> Misuse of alcoholic beverages resulting in negative consequences

Alcohol abuse encompasses a spectrum of unhealthy drinking behaviors which range from consuming more than 2 drinks per day on average for men, or more than 1 drink per day on average for women, to binge drinking or alcohol use disorder.

<span class="mw-page-title-main">Disulfiram</span> Chemical compound

Disulfiram is a medication used to support the treatment of chronic alcoholism by producing an acute sensitivity to ethanol. Disulfiram works by inhibiting the enzyme aldehyde dehydrogenase, causing many of the effects of a hangover to be felt immediately following alcohol consumption. Disulfiram plus alcohol, even small amounts, produces flushing, throbbing in the head and neck, a throbbing headache, respiratory difficulty, nausea, copious vomiting, sweating, thirst, chest pain, palpitation, dyspnea, hyperventilation, fast heart rate, low blood pressure, fainting, marked uneasiness, weakness, vertigo, blurred vision, and confusion. In severe reactions there may be respiratory depression, cardiovascular collapse, abnormal heart rhythms, heart attack, acute congestive heart failure, unconsciousness, convulsions, and death.

<span class="mw-page-title-main">Claudia Christian</span> American actress (born 1965)

Claudia Christian is an American actress, singer, and author, known for her roles as Commander Susan Ivanova on Babylon 5, as Captain Maynard on Fox's 9-1-1, and as the voice of Hera on the Netflix series Blood of Zeus. She is also the voice of Lt. Helga Sinclair in Atlantis: The Lost Empire. She is the founder and CEO of the C Three Foundation, a proponent of the medication-based Sinclair Method for treating alcohol dependence.

<span class="mw-page-title-main">Alcohol dependence</span> Medical condition

Alcohol dependence is a previous psychiatric diagnosis in which an individual is physically or psychologically dependent upon alcohol.

"The Hellgramite Method" is the forty-second episode and the seventh episode of the third season (1988–89) of the American television series The Twilight Zone. In this episode, an alcoholic has a vicious alcohol-consuming parasite implanted in him.

<span class="mw-page-title-main">Naltrexone</span> Medication

Naltrexone, sold under the brand name Revia among others, is a medication primarily used to manage alcohol use or opioid use disorder by reducing cravings and feelings of euphoria associated with substance use disorder. It has also been found effective in the treatment of other addictions and may be used for them off-label. An opioid-dependent person should not receive naltrexone before detoxification. It is taken by mouth or by injection into a muscle. Effects begin within 30 minutes, though a decreased desire for opioids may take a few weeks to occur. Side effects may include trouble sleeping, anxiety, nausea, and headaches. In those still on opioids, opioid withdrawal may occur. Use is not recommended in people with liver failure. It is unclear if use is safe during pregnancy. Naltrexone is an opioid antagonist and works by blocking the effects of opioids, including both opioid drugs as well as opioids naturally produced in the brain.

<span class="mw-page-title-main">Apomorphine</span> Chemical compound

Apomorphine, sold under the brand name Apokyn among others, is a type of aporphine having activity as a non-selective dopamine agonist which activates both D2-like and, to a much lesser extent, D1-like receptors. It also acts as an antagonist of 5-HT2 and α-adrenergic receptors with high affinity. The compound is historically a morphine decomposition product made by boiling morphine with concentrated acid, hence the -morphine suffix. Contrary to its name, apomorphine does not actually contain morphine or its skeleton, nor does it bind to opioid receptors. The apo- prefix relates to it being a morphine derivative ("[comes] from morphine").

<span class="mw-page-title-main">Opioid antagonist</span> Receptor agonist that acts on one or more of the opioid receptors

An opioid antagonist, or opioid receptor antagonist, is a receptor antagonist that acts on one or more of the opioid receptors.

<span class="mw-page-title-main">Acamprosate</span> Medication

Acamprosate, sold under the brand name Campral, is a medication used along with counseling to treat alcohol use disorder.

The modern disease theory of alcoholism states that problem drinking is sometimes caused by a disease of the brain, characterized by altered brain structure and function. Today, alcohol use disorder (AUD) is used as a more scientific and suitable approach to alcohol dependence and alcohol-related problems.

<span class="mw-page-title-main">Nalmefene</span> Opioid antagonist

Nalmefene is a medication that is used in the treatment of opioid overdose and alcohol dependence. Nalmefene belongs to the class of opioid antagonists and can be taken by mouth, administered by injection, or delivered through nasal administration.

Bankole A. Johnson, DSc, MD, MPhil, FRCPsych is a Nigerian psychiatrist. He served as Alumni Professor and Chairman of the Department of Psychiatry and Neurobehavioral Sciences at the University of Virginia and is known for his research into addiction.

Olivier Ameisen was a French-American cardiologist who wrote a best-selling book about curing alcoholism using the drug baclofen.

<span class="mw-page-title-main">Charles P. O'Brien</span> American research scientist, medical educator (born 1939)

Charles P. O'Brien is a research scientist, medical educator and a leading expert in the science and treatment of addiction. He is board certified in neurology, psychiatry and addiction psychiatry. He is currently the Kenneth E. Appel Professor of Psychiatry, and vice chair of psychiatry, in the Perelman School of Medicine at the University of Pennsylvania.

Subjective response to alcohol (SR) refers to an individual's unique experience of the pharmacological effects of alcohol and is a putative risk factor for the development of alcoholism. Subjective effects include both stimulating experiences typically occurring during the beginning of a drinking episode as breath alcohol content (BAC) rises and sedative effects, which are more prevalent later in a drinking episode as BAC wanes. The combined influence of hedonic and aversive subjective experiences over the course of a drinking session are strong predictors of alcohol consumption and drinking consequences. There is also mounting evidence for consideration of SR as an endophenotype with some studies suggesting that it accounts for a significant proportion of genetic risk for the development of alcohol use disorder.

<span class="mw-page-title-main">Alcohol and pregnancy</span> Medical condition

Alcohol use in pregnancy includes use of alcohol at any time during gestation, including the time before a mother-to-be is aware that she is pregnant. Alcohol use at some point during pregnancy is common and appears to be rising in prevalence in the United States.

John David Sinclair was an American scientist and researcher best known for discovering the Alcohol Deprivation Effect (ADE) and targeted pharmacological extinction, otherwise known as the Sinclair Method, as a medication treatment for Alcohol Use Disorder (AUD).

<span class="mw-page-title-main">Joseph R. Volpicelli</span> American psychiatrist

Joseph R. Volpicelli is an American psychiatrist, research scientist, medical academic, and expert in the treatment of addictive disorders. He is Professor Emeritus, Perelman School of Medicine at the University of Pennsylvania. He is board certified in neurology, psychiatry and addiction psychiatry. He currently is Medical Director at Volpicelli Center, an out-patient addiction treatment facility in Plymouth Meeting, Pennsylvania, as well as the Executive Director at Institute of Addiction Medicine, a non-profit research entity also in Plymouth Meeting, Pennsylvania.

References

  1. 1 2 3 4 5 "One Little Pill • Indiegogo". Indiegogo. Retrieved December 22, 2013.
  2. 1 2 3 4 5 6 "One Little Pill". C Three Foundation. Retrieved September 19, 2014.
  3. Garry B. "Exciting news: One Little Pill now an IndieGogo campaign!". Naltrexone Confidential. Retrieved December 22, 2013.
  4. D. (Lovinglife52), Michael (November 27, 2014). "One Little Pill (review)". Recovering from Recovery. Archived from the original on October 5, 2016. Retrieved August 7, 2015.{{cite web}}: CS1 maint: numeric names: authors list (link) CS1 maint: unfit URL (link)
  5. 1 2 3 Claudia Christian; Morgan Grant Buchanan; Dr. Roy Eskapa (2012). Babylon Confidential (First ed.). BenBella Books, Inc. pp. Afterword. ISBN   978-1-937856-06-9.
  6. John David Sinclair (January 1, 2001). "Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism". Alcohol and Alcoholism. 36 (1): 2–10. doi: 10.1093/alcalc/36.1.2 . PMID   11139409.
  7. "Contral Clinic treatment FAQ". Archived from the original on December 19, 2011. Retrieved April 14, 2015.
  8. "About The Sinclair Method". C Three Foundation. Retrieved September 28, 2014.
  9. "One Little Pill • Facebook". Facebook. Retrieved July 7, 2014.
  10. "Prisma: Lääke alkoholismiin?". YLE TV (in Finnish). Areena TV. Retrieved August 7, 2015.
  11. "HollyShorts Festival Genius - One Little Pill". HollyShorts Film Festival. Retrieved August 10, 2014.
  12. Cynthia Griffing (September 2, 2014). "Hollyshorts to Embark on a New Decade!". The Hollywood Times. Retrieved September 4, 2014.
  13. "C Three Foundation • The Sinclair Method (TSM)" . Retrieved December 22, 2013.